20 results
8-K
EX-99.1
ARAV
Aravive Inc
11 Oct 22
Aravive Receives Third Development Milestone from 3D Medicines
7:05am
together to improve patient survival and bring hope to women with advanced ovarian cancer.”
Aravive’s collaboration and license agreement with 3D
8-K
EX-99.1
ARAV
Aravive Inc
15 Jul 21
Aravive Achieves Second Development Milestone from 3D Medicines
7:05am
(3D-299) in China. Our companies are dedicated and working together to improve patient survival and bring hope to women with advanced ovarian cancer
8-K
EX-99.2
ARAV
Aravive Inc
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am
Ovarian Cancer (PROC); Patients Have Advanced Disease and High Mortality 5th LEADING CAUSE OF DEATH among women in the U.S. ~70% OF PATIENTS are diagnosed
8-K
EX-99.2
ARAV
Aravive Inc
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
Ovarian Cancer (PROC); Patients Have Advanced Disease and High Mortality 5th LEADING CAUSE OF DEATH among women in the U.S. ~70% OF PATIENTS
8-K
EX-99.1
1ni2f
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
u0ybyjs1b iv2
8 Mar 21
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma
7:05am
8-K
EX-99.1
adknayj
2 Mar 21
Regulation FD Disclosure
8:00am
8-K
EX-99.2
dbvl71p6q9 psdt4n
19 Nov 20
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
381g1j8ox641jp
8 Oct 20
Regulation FD Disclosure
5:01pm
8-K
EX-99.1
j4fgjk63rn 9wmfd
18 Feb 20
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
8:10am
8-K
EX-99.1
lh8k9p
20 Nov 19
Other Events
7:05am
8-K
EX-99.2
jru6doakraxriey mzv
27 Sep 19
Other Events
10:15am
8-K
EX-99.1
wdf36s
31 Jul 19
Aravive Reports Preliminary Results ofAVB-500 from the First Cohort of the Phase 1b/Phase 2 Recurrent Platinum Resistant Ovarian Cancer Trial
7:15am
8-K
EX-99.1
2jv 8kelvqj3o
8 Jul 19
Other Events
7:16am
8-K
EX-99.1
f20 73uc9w6
8 May 19
Aravive Reports First Quarter 2019 Financial Results and Provides Recent Corporate Updates
4:15pm
S-4
kom3x12 v1ws2i
3 Aug 18
Registration of securities issued in business combination transactions
5:26pm
- Prev
- 1
- Next